5 / 12
Page 27
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Biography
Brian G. Hubka is the CEO of Contamination Prevention Tech-
nologies, Inc. This company provides a vast array of contam-
ination remediation and prevention technologies and products
to eliminate and prevent mold, bacteria, viruses, prions and the
like.They are also specialists in biofilm remediation and elimina-
tion. He also consults on contamination issues in pharmaceuti-
cal and biotechnology companies. Has worked with Pfizer, Am-
gen, Celgene and many others. He is a graduate of University of
Notre Dame pre-medicine. He is also a frequent speaker and
has authored book chapters for many PDA/DHI books.
bhubka@contaminationprevention.comContamination Prevention
Brian G Hubka
Contamination Prevention Technologies, USA
Brian G Hubka, Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-005
Contamination Prevention is a common occurrence costing time delays for
product release, product rejection by quality and product recall by the FDA.
There are several new technologies that can quickly and completely eliminate
contamination:
• How to prevent certain types of contamination
• Identify extremely effective disinfectants that don’t harm stainless steel
• Identify easier methods to validate cleaning and disinfection using
biological indicators
• Preventing and eliminating biofilm with ambient water.
Prevention, Effective, Easy, Biofilm
Euro Vaccines 2018